US Merger & Acquisition SEC Filings — June 12, 2026
The June 12, 2026, US M&A digest reveals a market dominated by SPAC activity, with 18 of 19 filings involving blank-check companies. The most critical development is the significant shareholder skepticism toward SPAC extensions, highlighted by Pantages Capital Acquisition Corp, where 66% of public shares were redeemed following an extension vote, leaving only $29M in trust. This contrasts with positive capital-raising events, including FutureCorp Space Acquisition 1 ($230M IPO) and Snow Rothschild Acquisition Corp ($200M IPO), indicating robust supply of new SPACs seeking targets. A notable non-SPAC transaction is Rocket Pharmaceuticals' $180M sale of a Priority Review Voucher, providing a non-dilutive capital infusion that extends its cash runway into Q2 2028. The period-over-period data from Ashford Hospitality Trust's asset sale shows a modest improvement in net losses, but the company remains deeply distressed with a $3.09B accumulated deficit. Overall, the digest points to a market with ample SPAC capital seeking deployment, but growing investor resistance to extensions without clear targets, creating a bifurcated environment where well-capitalized SPACs with strong management may have an advantage in negotiating deals.